Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2024-09-11 Major Shareholding Noti…
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 8094D' by Oxford BioDynamics PLC on 11 September 2024. This form is used to report changes in significant share ownership (crossing thresholds) by a shareholder (Spreadex LTD). This directly corresponds to the definition of a Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a formal notification of ownership change, making MRQ the most precise classification over the general RNS fallback.
2024-09-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to voting rights, share thresholds, and notification dates (21.08.2024 and 22.08.2024). This structure is characteristic of regulatory filings concerning changes in significant share ownership, which corresponds to the Major Shareholding Notification category (MRQ). The presence of 'RNS Number' and the footer mentioning the London Stock Exchange and FCA confirms its nature as a regulatory disclosure.
2024-08-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 4580B' by Oxford BioDynamics PLC on August 22, 2024. This form is used to report changes in significant share ownership (crossing thresholds) by an entity (Spreadex LTD). This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a mandatory regulatory disclosure about share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2024-08-22 English
OBD pursuing EpiSwitch as companion diagnostics
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 7401X' and the date '25 July 2024', indicating it is a regulatory news service announcement. The content describes an upcoming presentation by Oxford BioDynamics at a conference regarding their EpiSwitch® products. This is not a full financial report (10-K or IR), an earnings release (ER), or a formal proxy/shareholder document. Since it is a general announcement released via the RNS system detailing company activities (a presentation schedule), and it doesn't fit into the more specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory announcement category, RNS.
2024-07-25 English
Grant of Options
Regulatory Filings Classification · 98% confidence The document is an RNS announcement (indicated by 'RNS Number' and the footer mentioning RNS, the news service of the London Stock Exchange). The content explicitly details the 'Grant of Share Options' to the CEO and other employees, including the number of options, exercise price, and vesting schedule. This type of transaction disclosure, especially concerning PDMR (Persons Discharging Managerial Responsibilities) dealings and share options, falls under insider trading or executive compensation disclosure requirements. While it relates to management, the core subject is the grant of options, which is a form of capital/financing activity or, more specifically, insider dealing/executive remuneration disclosure. Given the specific content detailing the grant to a Director/PDMR and the required disclosure format under UK Market Abuse Regulation, it strongly aligns with insider transaction reporting. The closest specific category is 'Director's Dealing' (DIRS), as PDMR dealing is a subset of insider transactions reported by directors. It is not a general regulatory filing (RNS) because a more specific category applies, and it is not a remuneration report (DEF 14A) which typically covers past compensation.
2024-06-21 English
Half-year Report
Interim / Quarterly Report Classification · 95% confidence The document is an official announcement from Oxford BioDynamics PLC regarding its 'Interim Results for the six-month period ended 31 March 2024'. It contains key financial highlights (revenue, operating loss, cash position), operational updates, and management commentary. While it is an announcement of interim results, it provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR) rather than a mere publication announcement (RPA). H1 2024
2024-06-18 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.